Table 5.
Distribution and adjusted odds ratios of asbestos exposure stratified by MIRLET7BHG genotypes for the risk of lung cancer from a pooled dataset
| SNP | Women and Men |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Exposed subjects (%) |
All Lung Cancer |
Lung Adenocarcinoma |
Lung Squamous |
|||||||
| All Lung Cancer Case |
Lung Adenocarcinoma |
Lung Squamous |
Control | OR (95%CI)a | p-value | OR (95%CI)a | p-value | OR (95%CI)a | p-value | |
| rs13053856 GG | 112 (17.8) | 46 (19.7) | 28 (19.7) | 114 (19.8) | 0.94 (0.86–1.03) | 1.74E-01 | 0.94 (0.83–1.06) | 3.26E-01 | 0.96 (0.83–1.11) | 5.83E-01 |
| GA+AA | 115 (23.1) | 47 (22.9) | 26 (33.3) | 63 (13.9) | 1.34 (1.18–1.51) | 3.13E-06 | 1.35 (1.15–1.58) | 1.91E-04 | 1.48 (1.22–1.80) | 6.74E-05 |
| rs11090910 TT | 527 (39.6) | 208 (39.3) | 170 (48.7) | 429 (37.0) | 1.05 (0.98–1.12) | 1.85E-01 | 1.02 (0.93–1.12) | 6.32E-01 | 1.14 (1.04–1.27) | 4.75E-03 |
| TC+CC | 485 (44.8) | 163 (40.5) | 165 (56.5) | 324 (35.3) | 1.24 (1.14–1.35) | 3.00E-07 | 1.18 (1.06–1.31) | 2.48E-03 | 1.31 (1.17–1.48) | 3.46E-06 |
| rs11703832 CC | 632 (39.6) | 254 (39.6) | 184 (45.7) | 497 (36.1) | 1.06 (0.99–1.13) | 8.28E-02 | 1.03 (0.95–1.12) | 5.07E-01 | 1.11 (1.01–1.22) | 2.35E-02 |
| CT+TT | 397 (44.4) | 126 (40.1) | 138 (59.7) | 263 (34.2) | 1.28 (1.17–1.40) | 1.41E-07 | 1.20 (1.07–1.35) | 1.93E-03 | 1.42 (1.25–1.61) | 3.15E-08 |
| rs12170325 CC | 643 (39.9) | 259 (39.5) | 188 (46.5) | 505 (36.3) | 1.06 (0.99–1.14) | 6.69E-02 | 1.04 (0.95–1.13) | 3.94E-01 | 1.11 (1.01–1.22) | 2.54E-02 |
| CT+TT | 410 (44.5) | 129 (40.7) | 151 (60.2) | 271 (34.4) | 1.26 (1.15–1.38) | 2.88E-07 | 1.20 (1.07–1.34) | 2.02E-03 | 1.38 (1.23–1.56) | 1.14E-07 |
| SNP | Women |
Men |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Lung Cancer |
Lung Adenocarcinoma |
Lung Squamous |
All Lung Cancer |
Lung Adenocarcinoma |
Lung Squamous |
|||||||
| OR (95%CI)b | p-value | OR (95%CI)b | p-value | OR (95%CI)b | p-value | OR (95%CI)b | p-value | OR (95%CI)b | p-value | OR (95%CI)b | p-value | |
| rs13053856 GG | 0.91 (0.81–1.02) | 1.16E-01 | 0.91 (0.78–1.05) | 1.77E-01 | 0.94 (0.80–1.11) | 4.75E-01 | 0.92 (0.78–1.09) | 3.41E-01 | 1.10 (0.85–1.42) | 4.75E-01 | 0.83 (0.57–1.20) | 3.14E-01 |
| GA+AA | 1.37 (1.16–1.62) | 2.55E-04 | 1.32 (1.10–1.59) | 3.23E-03 | 1.39 (1.11–1.73) | 3.51E-03 | 1.05 (0.86–1.28) | 6.33E-01 | 1.36 (0.99–1.86) | 5.74E-02 | 1.69 (1.12–2.55) | 1.21E-02 |
| rs11090910 TT | 0.92 (0.82–1.03 | 1.32E-01 | 0.92 (0.80–1.06) | 2.69E-01 | 0.97 (0.83–1.14) | 7.21E-01 | 1.17 (1.06–1.28) | 1.32E-03 | 1.21 (1.07–1.37) | 2.55E-03 | 1.26 (1.10–1.43) | 4.79E-04 |
| TC+CC | 1.31 (1.13–1.52) | 4.50E-04 | 1.27 (1.07–1.50) | 5.19E-03 | 1.34 (1.11–1.63) | 2.99E-03 | 1.18 (1.06–1.31) | 1.63E-03 | 1.12 (0.97–1.29) | 1.16E-01 | 1.24 (1.07–1.44) | 3.88E-03 |
| rs11703832 CC | 0.95 (0.85–1.05) | 2.98E-01 | 0.94 (0.82–1.07) | 3.61E-01 | 0.96 (0.83–1.12) | 6.14E-01 | 1.15 (1.06–1.26) | 1.42E-03 | 1.17 (1.04–1.31) | 6.70E-03 | 1.20 (1.06–1.36) | 3.80E-03 |
| CT+TT | 1.31 (1.11–1.54) | 1.16E-03 | 1.27 (1.07–1.52) | 7.92E-03 | 1.40 (1.13–1.72) | 1.64E-03 | 1.19 (1.07–1.34) | 1.88E-03 | 1.14 (0.97–1.33) | 1.09E-01 | 1.36 (1.17–1.59) | 9.45E-05 |
| rs12170325 CC | 0.95 (0.85–1.05) | 3.02E-01 | 0.94 (0.82–1.07) | 3.58E-01 | 0.96 (0.83–1.12) | 6.36E-01 | 1.16 (1.06–1.26) | 1.41E-03 | 1.18 (1.06–1.32) | 3.23E-03 | 1.20 (1.06–1.36) | 4.97E-03 |
| CT+TT | 1.31 (1.11–1.54) | 1.20E-03 | 1.28 (1.08–1.52) | 7.35E-03 | 1.40 (1.14–1.72) | 1.51E-03 | 1.18 (1.06–1.31) | 3.25E-03 | 1.13 (0.97–1.31) | 1.26E-01 | 1.31 (1.13–1.51) | 3.90E-04 |
a
Odds ratios and confidence intervals were calculated for one unit of increase in the log-transformed asbestos exposure score by mixed-effects logistic regression adjusted for age, sex, smoking status, and center.
b
Odds ratios and confidence intervals were calculated for one unit of increase in the log-transformed asbestos exposure score by mixed-effects logistic regression adjusted for age, smoking status, and center.